Proinflammatory cytokine production in activated human peripheral blood mononuclear cells (PBMC cytokine production)

Proinflammatory cytokine production in activated human peripheral blood mononuclear cells (PBMCs) is a complex biological process rather than a single molecular target. PBMCs, which include lymphocytes (T cells, B cells, NK cells) and monocytes, respond to activating stimuli such as lipopolysaccharide (LPS) or T-cell receptor ligation by secreting a cascade of inflammatory mediators like TNF-alpha, IL-6, and IL-1 beta (Source: PubMed, PMID: 28250305). This process is regulated by various intracellular signaling pathways, most notably the NF-kappaB, MAPK, and JAK/STAT pathways, which control the transcription and translation of cytokine genes (Source: NIH, StatPearls). In drug discovery, this is a critical phenotypic endpoint used to screen for anti-inflammatory and immunomodulatory agents. Excessive or chronic production of these cytokines is a key driver in the pathogenesis of autoimmune and autoinflammatory diseases, including rheumatoid arthritis and sepsis (Source: Nature Reviews Immunology). Therapeutic intervention typically involves targeting specific intracellular signaling molecules or using monoclonal antibodies to neutralize the cytokines post-secretion.

Other names

Cytokine release assayPBMC activationInflammatory cytokine secretionLPS-induced cytokine productionImmune cell cytokine release

Inhibition of intracellular signaling pathways (e.g., NF-kappaB, JAK/STAT, MAPK) or direct neutralization of secreted proinflammatory proteins to reduce the overall inflammatory output.